25 January 2024 - Liquidia announced today that the US FDA provided an update on its review of the new drug application for Yutrepia (treprostinil) inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. 

The FDA informed the Company that it is confirming the process for adding the pulmonary hypertension associated with interstitial lung disease indication as an amendment to the new drug application for Yutrepia.

Read Liquidia Technologies press release